Millendo Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome March 19, 2019
Millendo Therapeutics Appoints Acceleron CEO Habib Dable to its Board of Directors September 25, 2018
Millendo Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with Classic CAH September 13, 2018
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company August 9, 2018
